4
Changes in Ownership
Aclaris Therapeutics, Inc. Filed Acc 0001209191-22-015829
Chief Scientific Officer acquired 76,250 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Monahan Joseph Chief Scientific Officer | 2022-03-01 | Option exercise | +13,750 | 101,051 | D | ||
| Monahan Joseph Chief Scientific Officer | 2022-03-01 | Option exercise | +50,000 | 151,051 | D | ||
| Monahan Joseph Chief Scientific Officer | 2022-03-02 | Option exercise | +12,500 | 163,551 | D | ||
| Derivatives | |||||||
| Monahan Joseph Chief Scientific Officer | 2022-03-01 | Grant or award · Employee Stock Option (Right to Buy) | +153,100 | 153,100 | D | ||
| Monahan Joseph Chief Scientific Officer | 2022-03-01 | Grant or award · Restricted stock units | +43,700 | 43,700 | D | ||
| Monahan Joseph Chief Scientific Officer | 2022-03-01 | Option exercise · Restricted stock units | −13,750 | 13,750 | D | ||
| Monahan Joseph Chief Scientific Officer | 2022-03-01 | Option exercise · Restricted stock units | −50,000 | 150,000 | D | ||
| Monahan Joseph Chief Scientific Officer | 2022-03-02 | Option exercise · Restricted stock units | −12,500 | 25,000 | D | ||
Loading xslF345X03/doc4.xml…